PHAT Phathom Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1783183 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY86.8%
TTM net income YoY69.8%
TTM EPS YoY73.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin80.7%
Operating margin-9.3%
Net margin-30.2%
FCF margin-7.7%
EBITDA margin-9.1%
Returns
ROE—
ROA-28.4%
ROIC (approx.)—
Asset turnover0.94x
Leverage & solvency
Liabilities / assets200.8%
Debt / equity—
Current ratio1.76x
Interest coverage-0.41x
Cash quality & payout
Operating cash flow / net income0.25x
Accruals ratio-21.3%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $175.11M | $55.25M | $682,000 | $0 | — |
| Cost of revenue | $22.60M | $7.97M | $167,000 | $0 | — |
| Gross profit | $152.51M | $47.28M | $515,000 | $0 | — |
| R&D expense | $32.78M | $34.08M | $49.90M | $71.44M | $72.34M |
| SG&A expense | $279.72M | $290.66M | $117.93M | $101.00M | $62.74M |
| Operating income | -$159.99M | -$277.47M | -$167.31M | -$172.44M | -$135.08M |
| Interest expense | $68.11M | $72.01M | $41.97M | $27.30M | $6.79M |
| Pretax income | -$221.25M | -$334.33M | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$221.25M | -$334.33M | -$201.59M | -$197.72M | -$143.88M |
| EBITDA | -$159.35M | -$276.67M | -$166.74M | -$171.82M | -$134.56M |
| EPS (basic) | -3.03 | -5.29 | -3.93 | -5.05 | -3.89 |
| EPS (diluted) | -3.03 | -5.29 | -3.93 | -5.05 | -3.89 |
| Weighted avg. shares (diluted) | 72.92M | 63.18M | 51.29M | 39.12M | 37.00M |
| Balance sheet | |||||
| Cash & equivalents | $129.97M | $297.26M | $381.39M | $155.38M | $183.26M |
| Receivables | $78.13M | $38.80M | $1.64M | $0 | — |
| Inventory | $5.52M | $3.21M | $1.21M | $0 | — |
| Current assets | $228.97M | $360.13M | $397.43M | $160.51M | $186.53M |
| PP&E, net | $1.06M | $1.48M | $2.15M | $1.21M | $650,000 |
| Total assets | $259.15M | $378.32M | $413.84M | $164.81M | $189.43M |
| Current liabilities | $132.04M | $85.73M | $38.78M | $26.24M | $18.92M |
| Short-term debt | $0 | $0 | $0 | $0 | — |
| Long-term debt | $209.09M | $201.41M | $137.84M | $95.26M | $89.67M |
| Total debt | $209.09M | $201.41M | $137.84M | $95.26M | $89.67M |
| Total liabilities | $697.32M | $631.90M | $486.60M | $239.62M | $117.28M |
| Shareholders' equity | -$438.17M | -$253.58M | -$72.76M | -$74.81M | $72.16M |
| Net debt | $79.11M | -$95.85M | -$243.55M | -$60.12M | -$93.59M |
| Shares outstanding | 71.42M | 68.52M | 57.97M | 41.47M | 30.51M |
| Cash flow statement | |||||
| Operating cash flow | -$166.78M | -$266.77M | -$137.58M | -$146.53M | -$148.46M |
| Capital expenditure | $229,000 | $135,000 | $1.63M | $1.04M | $328,000 |
| Free cash flow | -$167.00M | -$266.90M | -$139.21M | -$147.57M | -$148.78M |
| Investing cash flow | -$229,000 | -$135,000 | -$1.63M | -$1.04M | -$328,000 |
| Financing cash flow | -$288,000 | $182.77M | $367.58M | $120.04M | $44.71M |
| Depreciation & amortization | $633,000 | $795,000 | $575,000 | $620,000 | $521,000 |
| Stock-based compensation | $28.72M | $24.05M | $45.02M | $24.13M | $16.81M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.